A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Aquafil's engineers and R&D team have found a way to separate what was once inseparable TRENTO, Italy - What was once considered impossible is now within reach. After more than ten years of relentless research and innovation, Aquafil has unveiled a breakthrough in...
Exclusively licensed from Queen's University Belfast (QUB), this composition of matter patent, one of the most robust forms of intellectual property protection, grants Niagen Bioscience exclusive rights to various salt forms of NR and derivatives LOS ANGELES - Niagen...
The rebrand celebrates the company's clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available LOS ANGELES - Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq...
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob...
Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial...
JERUSALEM, Feb. 24, 2025 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in AI-powered orthodontic solutions, today announced the successful completion of user experience trials for its ZSmile platform ahead of its commercial release....
JERUSALEM, Feb. 04, 2025 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in AI-powered orthodontic solutions, today announced a strategic partnership with Aran Research & Development, a premier Israel-based medical device developer...
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025...